Skip to Main content Skip to Navigation
Journal articles

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial

Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-02299505
Contributor : Dominique Chadeyron <>
Submitted on : Friday, September 27, 2019 - 5:46:56 PM
Last modification on : Monday, April 5, 2021 - 5:06:02 PM

Identifiers

Collections

Citation

Anne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, Valérie Rouillé, Béatrice Mahé, et al.. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. The Lancet Haematology, Elsevier, 2019, 6 (9), pp.e470-e479. ⟨10.1016/S2352-3026(19)30113-9⟩. ⟨hal-02299505⟩

Share

Metrics

Record views

82